TAE-684 effectively inhibits the growth of H3122 in vivo.

Slides:

Advertisements

Similar presentations

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Advertisements

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)

Figure S3. in vivo Study of ABT-263 or SAR in the RS4;11 model in mice

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Supplemental Figure 6 Supplemental Figure 6. Treatment with erlotinib plus TAS-115 inhibits the growth of PC-9/HGF tumors in vivo. (A, B) Nude mice bearing.

MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.

Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Activity of MAC-321 (i. v. and p. o

Effect of MI-773 dosing on long-term efficacy.

Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer. Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer.

IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.

Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.

TFAP2A knockdown inhibits tumor growth in vivo.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

Effects of AG on the colon histology score in the acute DSS colitis model. Effects of AG on the colon histology score in the acute DSS colitis model. Ten.

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,

The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. A, phospho-protein.

coTCRcys-transduced T cells control tumor growth in vivo.

In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Matriptase-2 inhibited breast tumor development in vivo.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Vascular staining in CWR22R xenograft tumors.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

Antitumor effects of celastrol in vitro and in vivo.

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

A, tumor growth studies in H1975 tumor–bearing mice.

Impairment of liver function upon treatment with 4D5MOCB-ETA.

CRA inhibits the growth of human tumor xenografts in vivo.

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

HMQ1611 inhibited breast tumor growth in mice.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Systemic reovirus treatment targets disseminated human myeloma in vivo

A and B, intratumoral DC-AdCCL21 leads to reduction in growth rates of bilateral tumors. A and B, intratumoral DC-AdCCL21 leads to reduction in growth.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Effect of CDV on human SF7796 xenografts in vivo.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Effect of dietary feeding of silibinin on DU145 tumor xenograft growth in athymic male nude mice. Effect of dietary feeding of silibinin on DU145 tumor.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

SW620 xenografts treated with combination siKRAS+siPIK3CA/B.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

BMX is a driver of castration resistance in vitro and in vivo.

PDL192 and inhibit the growth of xenograft tumors.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Survival RR enhancement according to the specific protocol in treated mice. Survival RR enhancement according to the specific protocol in treated mice.

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

Inhibition of spontaneous pulmonary metastasis and prolonged survival after removal of primary tumor and intratracheal delivery of rAAV2/5-VAS. Inhibition.

W. chinensis extract attenuates tumor growth of 103E (a subline of CWR22Rv1) engrafted in the prostate of nude mice. W. chinensis extract attenuates tumor.

In vivo effect of KIN-193 on PTEN-deficient tumors.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Curative effect of W+T treatment in vivo.

ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared.

DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.

Tumor growth in female progeny with prenatal/maternal, postnatal early-life, and postnatal adult BSp dietary administrations. Tumor growth in female progeny.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

TAE-684 effectively inhibits the growth of H3122 in vivo. TAE-684 effectively inhibits the growth of H3122 in vivo. Xenografts on H3122 in nu/nu mice were generated as described in Materials and Methods. Erlotinib and TAE-684 treatments were administered by oral gavage and tumors were measured three times weekly. The control and erlotinib-treated mice reached a median tumor size of 2,000 mm3 by 15 d of treatment and were sacrificed. In contrast, the median tumor size of mice treated with TAE684 at either 10 or 25 mg/kg/d did not reach 2,000 mm3 even after 53 days of treatment. Jussi P. Koivunen et al. Clin Cancer Res 2008;14:4275-4283 ©2008 by American Association for Cancer Research